Article
Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy.
Rheumatology (Oxford, England) - 6 Oct 2022
Shah Ankoor, Storek Jan, Woolson Rob, Pinckney Ashley, Keyes-Elstein Lynnette, Wallace Paul K, Sempowski Gregory D, McSweeney Peter, Mayes Maureen D, Crofford Leslie, Csuka M E, Phillips Kristine, Khanna Dinesh, Simms Robert, Ballen Karen, LeClercq Sharon, Clair William St, Nixon Andrew B, Nash Richard, Wener Mark, Brasington Richard, Silver Richard, Griffith Linda M, Furst Daniel E, Goldmuntz Ellen, Sullivan Keith M
Abstract excerpt
OBJECTIVES: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial compared hematopoietic stem cell transplant to CYC treatment in patients with early SSc with progressive skin and lung or kidney involvement. Here we describe lymphocyte phenotype abnormalities at study entry and the relation to prior DMARD therapy. METHODS: Lymphocyte subsets (n = 26) measured by flow cytometry were compared in 123...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.